Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | TPH1 | P17752 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.47 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606896 | 1.00 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL21690091 | 1.00 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| Trifluoroacetic Acid SCHEMBL1676739 | 0.93 | GRB2 (0.53) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL31369586 | 0.86 | GRIA2 (0.66) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL31370046 | 0.85 | CYP11B1 (0.52) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL93495 | 0.84 | SLC7A5 (0.78) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL180272 | 0.84 | SLC7A5 (0.78) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL414363 | 0.84 | SLC7A5 (0.78) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL93494 | 0.84 | SLC7A5 (0.78) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL1796036 | 0.84 | SLC7A5 (0.78) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | claimed |
| EP-1572892-A4 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-22 | — | — | EP | claimed |
| EP-1615653-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2006-01-18 | — | — | EP | claimed |
| EP-1572892-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2005-09-14 | — | — | EP | claimed |
| CN-1630709-A | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2005-06-22 | — | — | CN | claimed |
| WO-2004094461-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040127423-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-01 | — | — | US | claimed |
| US-20030195157-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-16 | — | — | US | claimed |
| WO-2003033671-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-24 | — | — | WO | claimed |
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | PEPTIDREAM INC. (JP) | 2025-11-27 | — | — | US | disclosed |
| EP-4541805-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | PeptiDream Inc. (JP) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023243120-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | ペプチドリーム株式会社 | 2023-12-21 | — | — | WO | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-6448408-B1 | CHEMICAL INTERMEDIATES IN PREPARATION OF N-MERCAPTOACYL DERIVATIVE OF PHENYLALANINE WITH PHARMALOGICAL ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2002-09-10 | — | — | US | disclosed |
| US-20020028946-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-PHENYLALANINES | ZAMBON GROUP S.P.A. (IT) | 2002-03-07 | — | — | US | disclosed |
| EP-0948492-B1 | PROCESS FOR THE PREPARATION OF HETEROARYL-PHENYLALANINES | ZAMBON SPA (IT) | 2001-07-11 | — | — | EP | disclosed |
| EP-0948492-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-PHENYLALANINES | ZAMBON GROUP S.p.A. (IT) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998028284-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-PHENYLALANINES | ZAMBON GROUP S.P.A. (IT) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | SLC7A5 3843/4885ALPI 251/4885PKM 2110/4885 |
| US-20030195157-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | GLP1R, IAPP, GIPR | SLC7A5 3672/4885ALPI 242/4885PKM 2080/4885 |
| US-20040127423-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | GLP1R, IAPP, GIPR | SLC7A5 3672/4885ALPI 242/4885PKM 2080/4885 |
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | BMP4, BMP1, BMPR2 | SLC7A5 2541/4885ALPI 2915/4885PKM 4179/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | SLC7A5 21/4885ALPI 3748/4885PKM 3544/4885 |
| US-20020028946-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-PHENYLALANINES | PAH, TYR, CYP2S1 | SLC7A5 51/4885ALPI 3466/4885PKM 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.